Pathophysiology of postoperative delirium and the use of biomimetic sleep as a treatment strategy in the CSICU
Pathophysiology of postoperative delirium and the use of biomimetic sleep as a treatment strategy in the CSICU
批准号:
10179061
负责人:
Oluwaseun Johnson-Akeju
金额:
$62.68万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-01 至 2023-05-31
关键词:
AcuteAgeAgingAlzheimer&aposs DiseaseAnesthesia proceduresAnestheticsAntipsychotic AgentsAstrocytesAttentionAwarenessBenzodiazepinesBindingBiological MarkersBiomimeticsBlood CirculationBlood specimenBrainCardiacCaringCellsChronicClinicalCognitionCognitive deficitsControl GroupsCritical IllnessDataDeliriumDementiaDevelopmentDexmedetomidineDiagnosisDiseaseElderlyElectroencephalogramFailureFunctional disorderHealth Care CostsHospitalizationHumanImpaired cognitionIncidenceIndividualInflammation MediatorsInflammatoryInstitutionalizationIntensive Care UnitsInterleukin-6InterventionInvestigationKnowledgeLaboratory AnimalsMagnetic Resonance ImagingMaintenanceMedicalMethodsMicrogliaMolecularMonitorMorbidity - disease rateMorphologyNerve DegenerationNeurogliaOperative Surgical ProceduresOutcomeOverdosePatientsPerioperativePharmaceutical PreparationsPharmacological TreatmentPharmacologyPositron-Emission TomographyProceduresProcessProteinsREM SleepRandomizedRandomized Controlled TrialsRiskRisk FactorsSepsisSerumSeveritiesSleepSleep DeprivationSleep disturbancesSurgical Intensive CareTherapeuticUnconscious StateUnited StatesWorkaging brainbasebrain dysfunctioncomorbidityexperiencemetabolic profilemodifiable riskmortalityneurocognitive disorderneuroinflammationneurophysiologynon rapid eye movementnormal agingolder patientpostoperative deliriumpreventradioligandstandard caresystemic inflammatory responsetreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Delirium is one of the six leading causes of preventable morbidity and mortality in hospitalized elderly patients.
Individuals with advanced age and Alzheimer's disease are at greatest risk of developing delirium. A
substantial proportion of patients who survive delirium are likely to experience long-term cognitive impairment
similar to mild Alzheimer's disease, and require institutional care. This suggests that delirium and Alzheimer's
disease share pathophysiological features that arise in the context of normal aging. Conditions associated with
delirium are characterized by activation of the inflammatory cascade with acute release of inflammatory
mediators into the bloodstream. A putative mechanism is the high interleukin-6 level that has been associated
with delirium in both laboratory animals and humans. Normal aging is associated with a morphological shift of
glia to an activated state. Following a systemic challenge such as critical illness, these activated glia result in
an exaggerated neuroinflammatory state associated with delirium. Neuroinflammation is further exacerbated by
sleep disturbances. Thus, sleep deprivation may be a modifiable risk factor for the development of delirium.
However, pharmacological treatment with no current medication (benzodiazepines, antipsychotics) induces
natural sleep or reliably reduces the incidence of delirium. We have found that biomimetic sleep, defined here
as pharmacological induction of rapid eye movement sleep (REM) and non-REM I-III sleep states using
dexmedetomidine, can now be achieved in humans. Our Specific Aims seek to: (1) investigate the benefits of
preemptive biomimetic sleep for reducing the risk of developing delirium in a randomize; (2) investigate the
cellular and molecular mechanisms of delirium using combined Positron Emission Tomography/Magnetic
Resonance imaging and serum metabolic profiling; and (3) investigate predictors of delirium from perioperative
electroencephalogram recordings. At the conclusion of these studies, we will have expanded our knowledge of
the pathophysiology of delirium, evaluated a new preemptive therapeutic strategy for delirium, suggest
neurophysiologically based monitoring strategies to reduce significantly the amount of anesthetic administered
to elderly patients – and possibly delirium – while being certain the patient is sufficiently unconscious for
surgery (individualized anesthesia care), and enable continued investigation into the pathophysiology of this
clinically important disorder.
期刊论文(18)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Sex Differences in the Incidence of Postoperative Delirium after Cardiac Surgery: A Pooled Analyses of Clinical Trials.
心脏手术后谵妄发生率的性别差异:临床试验的汇总分析。
DOI:
10.1097/aln.0000000000004656
发表时间:
2023
期刊:
Anesthesiology
影响因子:
8.8
作者:
[Wiredu,Kwame, Mueller,Ariel, McKay,TinaB, Behera,Alkananda, Shaefi,Shahzad, Akeju,Oluwaseun]
通讯作者:
Akeju,Oluwaseun
DOI:
10.1136/bmjopen-2017-020316
发表时间:
2018-04-20
期刊:
BMJ open
影响因子:
2.9
作者:
[Shelton KT, Qu J, Bilotta F, Brown EN, Cudemus G, D'Alessandro DA, Deng H, DiBiasio A, Gitlin JA, Hahm EY, Hobbs LE, Houle TT, Ibala R, Loggia ML, Pavone KJ, Shaefi S, Tolis G, Westover MB, Akeju O]
通讯作者:
Akeju O
DOI:
10.1111/jsr.13322
发表时间:
2021-10
期刊:
Journal of sleep research
影响因子:
4.4
作者:
[Ibala R, Mekonnen J, Gitlin J, Hahm EY, Ethridge BR, Colon KM, Marota S, Ortega C, Pedemonte JC, Cobanaj M, Chamadia S, Qu J, Gao L, Barbieri R, Akeju O]
通讯作者:
Akeju O
DOI:
10.1097/ccm.0000000000003400
发表时间:
2018-12
期刊:
Critical care medicine
影响因子:
8.8
作者:
[Fadayomi AB, Ibala R, Bilotta F, Westover MB, Akeju O]
通讯作者:
Akeju O
DOI:
10.1093/gerona/glab272
发表时间:
2022-03-03
期刊:
The journals of gerontology. Series A, Biological sciences and medical sciences
影响因子:
--
作者:
[Ulsa MC, Xi Z, Li P, Gaba A, Wong PM, Saxena R, Scheer FAJL, Rutter M, Akeju O, Hu K, Gao L]
通讯作者:
Gao L
共 13 条
Investigation of a Novel Biomarker of Postoperative Delirium
-
批准号:10452901
-
项目类别:
-
资助金额:$21.0万
-
财政年份:2022
-
负责人:Oluwaseun Johnson-Akeju
-
依托单位:
Investigation of a Novel Biomarker of Postoperative Delirium
-
批准号:10640891
-
项目类别:
-
资助金额:$25.2万
-
财政年份:2022
-
负责人:Oluwaseun Johnson-Akeju
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: